Abstract:BACKGROUND: Despite the recommendation of inhaled corticosteroids (ICSs) plus long-acting beta 2-agonist (LABA) and leukotriene receptor antagonist (LTRA) or ICS/LTRA as stepwise approaches in asthmatic children, there is a lack of published systematic review comparing the efficacy and safety of the two therapies in children and adolescents aged 4 to 18 years. This study aimed to compare the safety and efficacy of salmeterol/fluticasone (SFC) vs. montelukast (MON), or combination of montelukast and fluticasone (MFC) in children and adolescents aged 4 to 18 years with bronchial asthma.METHODS: A systematic search was conducted in MEDLINE, EMBASE, the Cochrane Library, China BioMedical Literature Database, Chinese National Knowledge Infrastructure, VIP Database for Chinese Technical Periodical, and Wanfang for randomized controlled trials (RCTs) published from inception to May 24, 2021. Interventions are as follows: SFC vs. MON, or combination of MFC, with no limitation of dosage or duration. Primary and secondary outcome measures were as follows: the primary outcome of interest was the risk of asthma exacerbation. Secondary outcomes included risk of hospitalization, pulmonary function, asthma control level, quality of life, and adverse events (AEs). A random-effects (I2 ≥ 50%) or fixed-effects model (I2 < 50%) was used to calculate pooled effect estimates, comparing the outcomes between the intervention and control groups where feasible.RESULTS: Of the 1006 articles identified, 21 studies met the inclusion criteria with 2643 individuals; two were at low risk of bias. As no primary outcomes were similar after an identical treatment duration in the included studies, meta-analysis could not be performed. However, more studies favored SFC, instead of MON, owing to a lower risk of asthma exacerbation in the SFC group. As for secondary outcome, SFC showed a significant improvement of peak expiratory flow (PEF)%pred after 4 weeks compared with MFC (mean difference [MD]: 5.45; 95% confidence interval [CI]: 1.57-9.34; I2 = 95%; P = 0.006). As for asthma control level, SFC also showed a higher full-controlled level (risk ratio [RR]: 1.51; 95% CI: 1.24-1.85; I2 = 0; P < 0.001) and higher childhood asthma control test score after 4 weeks of treatment (MD: 2.30; 95% CI: 1.39-3.21; I2 = 72%; P < 0.001) compared with MFC.CONCLUSIONS: SFC may be more effective than MFC for the treatment of asthma in children and adolescents, especially in improving asthma control level. However, there is insufficient evidence to make firm conclusive statements on the use of SFC or MON in children and adolescents aged 4 to 18 years with asthma. Further research is needed, particularly a combination of good-quality long-term prospective studies and well-designed RCTs.PROSPERO REGISTRATION NUMBER: CRD42019133156.

Clinical efficacy of montelukast sodium combination therapy for cough variant asthma in children: A meta‐analysis

A Multicenter, Prospective, Observational Study On Montelukast Monotherapy Or Montelukast-Based Combinations Treating Cough Variant Asthma

Efficacy and Safety of Montelukast Adjuvant Therapy in Adults with Cough Variant Asthma: A Systematic Review and Meta-Analysis.

A Meta-analysis of salmeterol fluticasone combined with montelukast in the treatment of asthma in children

Leukotriene receptor antagonist in children cough variant asthma

Clinical efficacy and safety of fluticasone/salmeterol inhalation powder combined with huaiqihuang granules in the treatment of children with cough variant asthma

Clinical Study Of The Treatment Of Variant Asthma In Children Through Nebulized Inhalation Of Montelukast Combined With Different Doses Of Budesonide Suspension

Retrospective, observational study of different medication regimens and outcome in children with cough variant asthma

Efficacy of montelukast sodium chewable tablets combined with inhaled budesonide in treating pediatric asthma and its effect on inflammatory factors.

Efficacy and safety of Montelukast-Levocetirizine Combination Therapy in Combined Allergic Rhinitis and Asthma Syndrome: A Systematic Review and Meta-Analysis

Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis

Efficacy of add-on montelukast in nonasthmatic eosinophilic bronchitis: the additive effect on airway inflammation, cough and life quality.

Meta Analysis Of the Efficacity and Security of Montelukast Combining with Budesonide Curing Asthma in Children

Treatment of Pediatric Mild Persistent Asthma with Low-Dose Budesonide Inhalation Suspension Vs.montelukast in China

Efficacy of Add-on Montelukast in Nonasthmatic Eosinophilic Bronchitis

Airway Inflammation, Bronchial Hyperresponsiveness, and Anti-Asthma Therapy Responses in Cough Variant Asthma and Classic Asthma with FEV1%≥80% Predicted

Efficacy of Pulmicort Turbuhaler Combined with Salbutamol in the Treatment of Children with Cough Variant Asthma

Children with mild to moderate asthma efficacy of montelukast therapy

Analysis of the clinical value of montelukast in treating the children with Infantile bronchial asthma

Exploring medication rules and mechanism of Chinese medicine for children with cough variant asthma based on data mining, network pharmacology, and molecular docking

Clinical observation of symptomatic treatment on pediatric cough varian asthma